License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended September 30,				Nine months ended September 30,
Partner	Drug or Drug Candidate	2013		2012		2013		2012
AstraZeneca AB	Naloxegol (NKTR-118) and naloxegol fixed-dose combination program (NKTR-119)	$	25,000	$	7	$	25,016	$	48
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		779		714		14,604		2,257
Roche	PEGASYS® and MIRCERA®		2,625		2,011		7,875		5,134
Affymax, Inc.	Omontys®		6,779		198		7,149		2,610
Amgen, Inc.	Neulasta®		1,250		1,250		3,750		3,750
Baxter Healthcare	BAX 855 (Hemophilia)		201		741		1,499		5,794
Other			4,726		1,211		7,302		4,597
License, collaboration, and other revenue		$	41,360	$	6,132	$	67,195	$	24,190